Ask for high quality link by putting your email below

Please, double check your email!

Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of some patients. Mutations impacting the MET receptor exon 14 splice sites (METex14) have recently been detected in about 3% of lung cancers and lead to the loss of the juxtamembrane domain with several negative regulatory sites. METex14 does not lead to constitutive activation of the receptor but we demonstrated that HGF, its ligand, is required for the full development of the transforming capabilities of the METex14 receptor in SCID-HGFhuman transgenic mice.
Several clinical trials have shown that only half of METex14 patients responded to MET inhibitors. While encouraging, these results are lower than those obtained with other treatments such as EGFR inhibitors. Interestingly, METex14 mutations are frequently associated with other molecular alterations including PTEN loss or TP53 mutations. Furthermore, we have shown that many METex14 mutated patients have autocrine secretion of HGF ligand. Understanding how these co-alterations impact METex14 oncogenicity and sensitivity to existing therapies is of outmost importance to identify patients that could benefit from them.
Frampton et al., 2015, Cancer Discov. – Togashi et al., 2015, Lung Cancer – Wolf et al., 2020, NEJM

Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

Feedback to the first OncoLille Days Congress - HCS Pharma · November 25, 2022 at 10:29 am

[…] example, Marie Fernandes, who works in OncoLille in collaboration with HCS Pharma, presented also a poster about her studies about lung cancer in BIOMIMESYS®. Her results showed that the in vitro behaviour of cancerous cells in BIOMIMESYS® […]

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.